Trial Profile
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2015
Price :
$35
*
At a glance
- Drugs BI 60732 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Sep 2014 New trial record